Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023… Read More
Vancouver, BC – WEX Pharmaceuticals Inc., a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that it has commenced its Quantitative Sensory Testing (QST) clinical trial and is… Read More
VAUGHAN, ON – LifeLabs, Canada’s leading provider of medical diagnostic services, is catering to the growing healthcare needs of Vaughan residents with the grand opening of a new Patient Service… Read More
VANCOUVER, BC – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, announces that the special meeting of its securityholders to be held this Monday,… Read More
EP-104IAR and EP-104GI continuing to advance clinically & remain on track Corporate initiatives ongoing to position EP-104IAR and EP-104GI for successful outcomes Company provides milestones for 2024 VICTORIA, BC — Eupraxia… Read More
